Showing results (2691-2700 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|January 1, 1987
Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trialM R Cooper, A Fefer, J Thompson, et al.
Investigational New Drugs|January 1, 1987
Treatment of metastatic malignant melanoma with recombinant interferon alfa-2bT Dorval, T Palangie, M Jouve, et al.
Investigational New Drugs|September 1, 2021
Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-AsparaginaseTapasvi Modi, David Gervais
Investigational New Drugs|August 9, 2022
Ketamine promotes breast tumor growth in a mouse breast tumor model involving with high expression of miR-27b-3p and EGFRLi-Kuei Chen, Chien-Hung Shih, Shiou-Sheng Chen, et al.
Investigational New Drugs|February 22, 2023
In vitro effects of gamma-secretase inhibition in HPV-positive and HPV-negative head and neck squamous cell carcinomaSara Varatanovic, Tobias Maier, Sega Al-Gboore, et al.
Investigational New Drugs|March 3, 2023
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumorsAntonio Jimeno, Joaquina Baranda, Wade T Iams, et al.
Investigational New Drugs|June 13, 2020
A randomized, double-blind, placebo-controlled study of B-cell lymphoma 2 homology 3 mimetic gossypol combined with docetaxel and cisplatin for advanced non-small cell lung cancer with high expression of apurinic/apyrimidinic endonuclease 1Yuxiao Wang, Xuemei Li, Liang Zhang, et al.
Investigational New Drugs|June 6, 2020
Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformaticsYing Zhang, Francesca Garofano, Xiaolong Wu, et al.
Investigational New Drugs|June 25, 2020
Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancerShunsuke Kondo, Masaomi Tajimi, Tomohiko Funai, et al.
Investigational New Drugs|May 22, 2020
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant gliomaDavid A Reardon, Annick Desjardins, Olivier Rixe, et al.
Pageof 372